




PHARMACEUTICAL 2021

FIBROGEN INC
Rank 210 of 402





PHARMACEUTICAL 2021

FIBROGEN INC Rank 210 of 402



The relative strengths and weaknesses of FIBROGEN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of FIBROGEN INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 30% points. The greatest weakness of FIBROGEN INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 94%, being 46% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	755,110
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	163,187
Liabilities, Non-Current	178,116
Other Assets	38,083
Other Compr. Net Income	-3,752
Other Expenses	9,229
Other Liabilities	44,088
Other Net Income	2,949
Other Revenues	176,319
Property and Equipment	33,647
Research and Development	252,924
Selling, General and Administrative Expense	106,406

Output Variable	Value in 1000 USD
Assets	826,840
Liabilities	385,391
Expenses	368,559
Revenues	176,319
Stockholders Equity	441,449
Net Income	-189,291
Comprehensive Net Income	-191,167
Economic Capital Ratio	94%